Use of recombinant factor VIIa in inherited and acquired von Willebrand disease

16Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Recombinant factor VIIa (rFVIIa) is increasingly used outside the labeled indications for the treatment of life-threatening bleeding episodes after failure of respective standard therapy. In this article, the authors focus on the use of the agent in patients with inherited or acquired von Willebrand disease (vWD). Although the current experience is sparse, published cases indicate the high efficacy of rFVIIa for the treatment of patients refractory to conventional treatment. The agent may be used in patients with congenital vWD complicated by alloantibodies directed against substituted von Willebrand factor or in the presence of concomitant hemostatic defects as well as acquired vWD with hitherto limited therapeutic options. Controlled clinical studies are necessary to define the use of rFVIIa in this clinical setting. © 2009 SAGE Publications.

Cite

CITATION STYLE

APA

Sucker, C., Scharf, R. E., & Zotz, R. B. (2009, February). Use of recombinant factor VIIa in inherited and acquired von Willebrand disease. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/1076029607310920

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free